Eli Lilly and Company (LLY) $878.24
Eli Lilly has plummeted into deeply oversold territory, losing over 22% from its 52-week high, leaving investors to ponder if this is a generational buying opportunity or a warning sign of deeper trouble ahead.
52-wk High $1133.95
📌 Investment Snapshot
- 💰 Trading at $878.24, LLY commands a $786.0B market cap with a 38.3x P/E ratio, significantly above the S&P 500 average.
- 📈 Latest quarter revenue hit $19.29B with $7.39 EPS, demonstrating robust top-line growth.
- 🔑 The GLP-1 drug pipeline remains the primary growth engine, underpinning strong future earnings expectations.
- 🎯 Analysts maintain a Strong Buy consensus with a mean target of $1209.34, implying +37.7% upside.
Eli Lilly has plunged into deeply oversold territory, with its RSI screaming for a bounce. However, the stock remains caught in a strong bearish trend, confirmed by ADX, and faces significant overhead resistance.
| 📍 Entry Zone | $860-$870 or below | 🛑 Stop-Loss | $845 |
| 📋 Adjust If | A sustained close above $900 on above-average volume would signal a potential trend reversal, warranting a re-evaluation of the short-term outlook. | ||
The Investment Case — Why Now?
Eli Lilly has experienced a sharp correction over the past three months, shedding over 18% of its value, largely driven by broader market volatility (VIX at 31.05) and potential profit-taking after a stellar run. This pullback has pushed the stock into extreme oversold conditions, presenting a critical juncture for investors. The question now is whether this dip offers a compelling entry or signals a deeper structural issue.
The primary risk challenging the immediate bullish thesis is the strong bearish momentum confirmed by the ADX at 42.1, coupled with the price trading below both its 50-day and 200-day moving averages. While the GLP-1 narrative remains robust, a sustained downtrend could see LLY test the $850 low analyst target, potentially triggering further technical selling.
🤔 Considering LLY’s robust pipeline and deep oversold status, are you willing to step into a strong bearish trend on the expectation of a bounce, or would you demand more definitive signs of a reversal?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | Eli Lilly and Company |
| Ticker / Exchange | LLY / NYSE |
| Sector / Industry | Healthcare / Drug Manufacturers – General |
| CEO | David Ricks |
| Founded / HQ | 1876 / Indianapolis, Indiana |
📈 Price Action & Technicals
Inside VA
Three recent buy-side liquidity sweeps occurred between $1002.46 and $1010.38 in February and early March, indicating institutional interest at higher price levels, but the stock has since declined significantly.
Eli Lilly’s price action paints a concerning picture in the short term, with the stock trading decisively below both its 50-day SMA ($1006.54) and 200-day SMA ($893.43). These key moving averages now act as formidable overhead resistance, challenging any immediate rebound efforts. The recent 22.6% drop from its 52-week high underscores the severity of the current downtrend.
The RSI at 15.4 screams deeply oversold, a level that historically precedes at least a short-term bounce. However, the ADX at 42.1 with a dominant -DI (44.7) confirms a strong bearish trend, suggesting that while a bounce is probable, it might be a relief rally within a larger downtrend. The MACD also remains in bearish territory, though the signal line hints at a potential deceleration of selling pressure.
The Anchored VWAP from August 2025 at $900.99 sits just above the current price, acting as an immediate resistance level. While the current price of $878.24 resides within the Volume Profile’s Value Area ($640.93-$1091.13), the Point of Control (POC) at $1060.44 indicates that the majority of trading volume occurred at much higher prices, suggesting significant bagholding above.
Volume has been running at average levels (0.98x), failing to confirm either strong buying or capitulation selling. The price is currently hugging the lower Bollinger Band ($863.29), a level often associated with short-term reversals. However, the presence of unfilled bearish FVG zones at $900.83-$909.09 and $929.0-$975.51 suggests potential magnet zones for price action on a bounce, but also formidable resistance.
🤔 Given the conflicting signals of an extremely oversold RSI against a strong bearish trend confirmed by ADX, what technical indicator would you prioritize for confirming a sustainable reversal in LLY?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| LLY | Eli Lilly and Company | 38.3x |
| NVO | Novo Nordisk A/S | 45.0x |
| JNJ | Johnson & Johnson | 23.5x |
| MRK | Merck & Co., Inc. | 18.0x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $19.29B | $7.39 | +51.5% |
| Q3 2025 | $17.60B | $6.21 | +38.4% |
| Q2 2025 | $15.56B | $6.29 | +22.3% |
| Q1 2025 | $12.73B | $3.06 | +10.0% |
Eli Lilly reported $0.3B in free cash flow for the latest quarter, alongside a significant $1.5B in share buybacks, signaling management’s confidence and commitment to returning value to shareholders despite the recent stock price volatility.
🚀 Growth Drivers — What Moves the Stock
- GLP-1 Dominance (Zepbound & Mounjaro) 🟢 Upside Surprise — Eli Lilly’s market leadership in the GLP-1 agonist space with Zepbound (weight loss) and Mounjaro (diabetes) continues to drive unprecedented revenue growth. These drugs are poised to capture a significant share of a rapidly expanding market, underpinning long-term earnings potential.
- Robust Pipeline & R&D 🟡 Priced In — The company maintains a deep and diversified pipeline beyond GLP-1s, focusing on oncology, immunology, and neuroscience. This strategic investment in R&D ensures future growth vectors and reduces reliance on a single drug class, providing a strong foundation for sustained innovation.
🤔 While LLY’s GLP-1 franchise is a clear growth engine, do you believe the market is fully appreciating the long-term revenue runway for these drugs, or are expectations still too conservative?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Lilly Endowment, Inc | 92,190 |
| Vanguard Group Inc | 81,965 |
| Blackrock Inc. | 66,792 |
| PNC Financial Services Group, Inc. | 51,333 |
| State Street Corporation | 35,361 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| ALVAREZ RALPH | Director | Mar 16, 2026 | Other | 12 |
| FYRWALD J. ERIK | Director | Mar 16, 2026 | Other | 10 |
| SULZBERGER GABRIELLE | Director | Mar 16, 2026 | Other | 5 |
| LUCIANO JUAN R | Director | Mar 16, 2026 | Other | 16 |
| DOZIER ERIC | Officer | Feb 19, 2026 | Other | 481 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 2.5 |
⚠ Key Risk Factors
~$50B market cap
~$100B revenue impact
~$150B market cap
~$75B market cap
🤔 With LLY’s premium valuation and intense GLP-1 competition, how much of a discount to its current price would you demand to compensate for these risks, even with its strong growth prospects?
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $1500.0 | $1209.34 | $850.0 | 29 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| HSBC | Reduce | $850 | Mar 2026 | Down |
| RBC Capital | Outperform | $1250 | Feb 2026 | Initiates |
| Barclays | Overweight | $1300 | Feb 2026 | Initiates |
| Freedom Broker | Buy | $1200 | Feb 2026 | Upgrades |
| Deutsche Bank | Buy | $1280 | Feb 2026 | Maintains |
The overwhelming analyst consensus for LLY remains 'Buy', with a mean target of $1209.34 implying substantial upside from current levels. However, the recent 'Reduce' rating from HSBC and a low target of $850 highlight growing concerns around valuation and potential downside risk.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- GLP-1 market expansion continues to exceed expectations, driving sustained double-digit revenue and EPS growth for LLY.
- Successful advancement of key pipeline assets in oncology and immunology provides new revenue streams, diversifying beyond the GLP-1 franchise.
📊 Base Case
Our base case assumes LLY’s GLP-1 franchise maintains its leadership position, delivering strong but moderating growth as competition intensifies. Pipeline advancements will contribute steadily, but the stock’s premium valuation will keep it sensitive to market sentiment and interest rate fluctuations. We project a fair value reflecting continued innovation tempered by market realities.
🐻 Bear Case
- Aggressive competition or unexpected regulatory hurdles significantly erode GLP-1 market share or pricing power, impacting core revenue streams.
- Major clinical trial failures or macroeconomic headwinds trigger a broader market downturn, disproportionately affecting high-valuation growth stocks.
🎯 Investor Action Plan — By Profile
Swing traders should avoid initiating new long positions until LLY demonstrates a clear break above the SMA200 at $893.43 on strong volume. The current strong bearish trend presents too much risk for short-term directional bets.
Position investors should stay on the sidelines for now. A more attractive entry window could emerge if LLY retests the $860-$870 range and shows signs of stabilization, or if it decisively reclaims the $900 Anchored VWAP.
Long-term investors with an existing position should hold onto their shares, provided their original thesis on LLY’s GLP-1 dominance and pipeline strength remains intact. Consider scaling into weakness only if the stock falls towards the $800-$820 range, representing a deeper value entry.
❓ Investor FAQ — People Also Ask
Q: Why has Eli Lilly’s stock dropped recently despite strong growth?
LLY’s recent 22% pullback from its 52-week high is likely a combination of broader market volatility (VIX at 31.05), profit-taking after a significant run, and concerns over its premium valuation (38.3x P/E). Despite robust fundamentals, high-growth stocks are often more susceptible to market corrections.
Q: Is LLY’s current oversold RSI a reliable signal for a bounce?
An RSI of 15.4 is extremely oversold, historically signaling a high probability of a short-term relief rally. However, the ADX at 42.1 confirms a strong bearish trend, indicating that any bounce might be temporary within a larger downtrend. Investors should look for further confirmation of a trend reversal.
Q: What are the key resistance levels LLY needs to overcome for a sustained recovery?
For a sustained recovery, LLY must first reclaim the Anchored VWAP at $900.99 and the 200-day SMA at $893.43. Beyond these immediate hurdles, the 50-day SMA at $1006.54 and unfilled bearish FVG zones between $900-$975 represent significant overhead resistance that price will likely struggle to overcome without strong buying pressure.
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The views expressed are solely those of the analyst and may not reflect the views of Goldman Sachs or its affiliates.
All active positions and their real-time performance are tracked on our Investment Log.
#LLY #EliLilly #PharmaStocks #GLP1 #StockAnalysis #Healthcare #USStocks #Investing